Cellular and Molecular Neurobiology Laboratory, Department of Life Science and Bioinformatics, Assam University, Silchar, 788011, Assam, India.
Department of Zoology, Pandit Deendayal Upadhyaya Adarsha Mahavidyalaya (PDUAM), Eraligool, 788723, Karimganj, Assam, India.
Neurochem Int. 2019 Sep;128:50-57. doi: 10.1016/j.neuint.2019.04.004. Epub 2019 Apr 12.
Garcinol, the principal phytoconstituent of plants belonging to the genus Garcinia, is known for its anti-oxidant as well as anti-inflammatory properties, which can be extended to its possible neuroprotective role. Recent reports disseminate the capacity of garcinol to influence neuronal growth and survival, alter the neurochemical status in brain, as well as regulate memory and cognition. The concomitant neuro-rescue property of garcinol may render it as an effective compound in Parkinson's disease (PD) therapeutics since it is capable of ameliorating the related pathophysiological changes. Emerging pieces of evidence linking histone acetylation defects to the progression of neurodegenerative diseases provide an effective basis for targeting PD. Hyperacetylation of histones has been reported in Parkinsonian brain, which demands the use of pharmacological inhibitors of histone acetyltransferases (HAT). Garcinol serves as a potent natural HAT inhibitor and has unveiled promising results in molecular interaction studies against Monoamine oxidase B (MAO-B) and Catechol-O-Methyltransferase (COMT), as well as in L-DOPA induced dyskinesia. This review highlights the prospective implications of garcinol as a novel anti-Parkinsonian agent, and establishes a bridge between histone acetylation defects and the pathological aspects of PD.
藤黄酚是藤黄属植物的主要植物成分，具有抗氧化和抗炎特性，其可能具有神经保护作用。最近的报告表明，藤黄酚能够影响神经元的生长和存活，改变大脑中的神经化学状态，以及调节记忆和认知。藤黄酚的神经保护作用可能使其成为治疗帕金森病 (PD) 的有效化合物，因为它能够改善相关的病理生理变化。将组蛋白乙酰化缺陷与神经退行性疾病的进展联系起来的新证据为靶向 PD 提供了有效的基础。帕金森病大脑中已经报道了组蛋白的过度乙酰化，这需要使用组蛋白乙酰转移酶 (HAT) 的药理学抑制剂。藤黄酚是一种有效的天然 HAT 抑制剂，在针对单胺氧化酶 B (MAO-B) 和儿茶酚-O-甲基转移酶 (COMT) 的分子相互作用研究以及 L-DOPA 诱导的运动障碍方面取得了有希望的结果。这篇综述强调了藤黄酚作为一种新型抗帕金森药物的前景，并在组蛋白乙酰化缺陷与 PD 的病理方面建立了联系。
